NeuroSense Therapeutics Ltd. (NRSN) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 2.35M | 2.35M | 1.77M | 2.11M | 3.03M | 2.99M | 3.29M | 2.9M | 3.48M | 2.99M | 3.38M | 3.32M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 1.09M | 1.09M | 685K | 946K | 1.46M | 1.11M | 1.33M | 1.27M | 1.57M | 1.14M | 1.83M | 1.61M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 1.25M | 1.25M | 1.09M | 1.16M | 1.57M | 1.88M | 1.96M | 1.63M | 1.91M | 1.85M | 1.54M | 1.71M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -2.35M | -2.35M | -1.77M | -2.11M | -3.03M | -2.99M | -3.29M | -2.9M | -3.48M | -2.99M | -3.38M | -3.32M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | 22.57% | 21.64% | 46.12% | 27.27% | 12.86% | -0.1% | 2.72% | 12.71% | 3.15% | 8.36% | -105.41% | - |
| EBITDA | -2.34M | -2.34M | -1.77M | -2.1M | -3.02M | -2.99M | -3.28M | 2.99M | -3.45M | -2.99M | -3.2M | -3.32M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 22.57% | 21.64% | 46.2% | -170.39% | 12.42% | -0.03% | -2.46% | 189.99% | 3.25% | 8.43% | -94.8% | - |
| D&A (Non-Cash Add-back) | 4K | 4K | 5.5K | 5.25K | 5.5K | 5.25K | 5.25K | 0 | 23.5K | 3K | 0 | 750 |
| EBIT | -2.35M | -2.35M | -1.77M | -2.11M | -857K | -2.99M | -5.15M | 2.99M | -5.53M | -2.61M | -3.2M | -2.98M |
| Net Interest Income | -8.5K | -8.5K | -30K | -41K | 2.17M | -2.41M | -2.06M | 3.68M | -276K | -243K | 206K | 325K |
| Interest Income | 0 | 0 | 0 | 0 | 2.17M | 0 | -3.72M | 3.69M | 0 | 67K | 206K | 335K |
| Interest Expense | 8.5K | 8.5K | 30K | 41K | 0 | 2.41M | -1.66M | 12K | 276K | 310K | 0 | 10K |
| Other Income/Expense | -8.5K | -8.5K | -30K | -41K | 2.17M | -2.41M | 337K | 3.68M | -1.75M | 67K | 229K | 325K |
| Pretax Income | -2.35M | -2.35M | -1.8M | -2.15M | -857K | -5.4M | -2.95M | 784K | -5.22M | -2.92M | -3.15M | -2.99M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -2.35M | -2.35M | -1.8M | -2.15M | -857K | -5.4M | -2.95M | 784K | -5.22M | -2.92M | -3.15M | -2.99M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -174.74% | 56.43% | 38.95% | -373.98% | 83.6% | -84.82% | 6.35% | 126.19% | -50.1% | -7.7% | -3018.81% | - |
| Net Income (Continuing) | -2.35M | -2.35M | -1.8M | -2.15M | -857K | -5.4M | -2.95M | 784K | -5.22M | -2.92M | -3.15M | -2.99M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.09 | -0.09 | -0.08 | -0.11 | -0.05 | -0.35 | -0.19 | 0.06 | -0.38 | -0.25 | -0.25 | -0.23 |
| EPS Growth % | -95.16% | 73.51% | 56.21% | -291.3% | 87.5% | -40% | 24% | 125% | -26.67% | -4.17% | - | - |
| EPS (Basic) | -0.09 | -0.09 | -0.08 | -0.11 | -0.05 | -0.35 | -0.19 | 0.06 | -0.38 | -0.25 | -0.25 | -0.23 |
| Diluted Shares Outstanding | 25.4M | 25.4M | 21.65M | 19.81M | 18.05M | 15.4M | 15.38M | 13.62M | 13.62M | 11.79M | 11.78M | 11.59M |
| Basic Shares Outstanding | 25.4M | 25.4M | 21.65M | 19.81M | 18.05M | 15.4M | 15.38M | 13.62M | 13.62M | 11.79M | 11.78M | 11.59M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |